Gilead's virology drug head named CEO of East Coast biotech AlloVir

Dr. Diana Brainard, a 10-year veteran of Gilead Sciences Inc. who currently heads up the company's broad virology drug pipeline, will take over as CEO of a young cell therapy company backed by her soon-to-be former employer. Starting May 17, Brainard will lead AlloVir Inc. (NASDAQ: ALVR), a Cambridge, Massachusetts, company working on off-the-shelf, virus-specific T cell therapy candidates, including the coronavirus that causes Covid-19. She will leave Foster City-based-based Gilead (NASDAQ: GILD)…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news